Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
age 18 Years to 80 Years
Item
age 18 Years to 80 Years
boolean
397669002 (SNOMED CT 2011_0131)
C0001779 (UMLS CUI-1)
Informed consent
Item
Informed consent
boolean
410671006 (SNOMED CT 2011_0131)
MTHU021546 (LOINC Version 232)
WRITTEN (HL7 V3 2006_05)
288556008 (SNOMED CT 2011_0131-2)
C0021430 (UMLS CUI-1)
Female infertility or Contraceptive methods
Item
Female infertility or Contraceptive methods
boolean
224526002 (SNOMED CT 2011_0131)
8619003 (SNOMED CT 2011_0131-2)
10021926 (MedDRA 14.1)
236886002 (SNOMED CT 2011_0131-3)
10021151 (MedDRA 14.1-2)
76498008 (SNOMED CT 2011_0131-4)
14302001 (SNOMED CT 2011_0131-5)
10001928 (MedDRA 14.1-3)
N91.2 (ICD-10-CM Version 2010)
626.0 (ICD-9-CM Version 2011)
258707000 (SNOMED CT 2011_0131-6)
Y (HL7 V3 2006_05)
146680009 (SNOMED CT 2011_0131-7)
10010808 (MedDRA 14.1-4)
59261009 (SNOMED CT 2011_0131-8)
225370004 (SNOMED CT 2011_0131-9)
1305003 (SNOMED CT 2011_0131-10)
C0021361 (UMLS CUI-1)
C0700589 (UMLS CUI-2)
Contraceptive methods
Item
partner using condom and subject using spermicide, diaphragm, intra-uterine device or contraceptive sponge) for 1 month prior to Visit 1 (screening visit) or longer if requested by the investigator. Women of childbearing potential must continue to practice birth control during the study and for at least 2 months after completing the study. Women of childbearing potential must have a negative pregnancy test at screening and Visit 2, 5, 7 and 9.
boolean
262043009 (SNOMED CT 2011_0131)
SIGOTHR (HL7 V3 2006_05)
260676000 (SNOMED CT 2011_0131-2)
260676000 (SNOMED CT 2011_0131-3)
425484006 (SNOMED CT 2011_0131-4)
20359006 (SNOMED CT 2011_0131-5)
268460000 (SNOMED CT 2011_0131-6)
10022745 (MedDRA 14.1)
169529008 (SNOMED CT 2011_0131-7)
258706009 (SNOMED CT 2011_0131-8)
MO (HL7 V3 2006_05-2)
288556008 (SNOMED CT 2011_0131-9)
ENC (HL7 V3 2006_05-3)
242762006 (SNOMED CT 2011_0131-10)
385644000 (SNOMED CT 2011_0131-11)
224526002 (SNOMED CT 2011_0131-12)
146680009 (SNOMED CT 2011_0131-13)
10010808 (MedDRA 14.1-2)
371881003 (SNOMED CT 2011_0131-14)
110465008 (SNOMED CT 2011_0131-15)
19338005 (SNOMED CT 2011_0131-16)
258706009 (SNOMED CT 2011_0131-17)
MO (HL7 V3 2006_05-4)
237679004 (SNOMED CT 2011_0131-18)
250425007 (SNOMED CT 2011_0131-19)
10036574 (MedDRA 14.1-3)
ENC (HL7 V3 2006_05-5)
C0700589 (UMLS CUI-1)
Asthma severe
Item
Uncontrolled (refractory) asthma despite optimal treatment
boolean
19032002 (SNOMED CT 2011_0131)
20646008 (SNOMED CT 2011_0131-2)
195967001 (SNOMED CT 2011_0131-3)
10003553 (MedDRA 14.1)
MTHU020815 (LOINC Version 232)
J45 (ICD-10-CM Version 2010)
493 (ICD-9-CM Version 2011)
439401001 (SNOMED CT 2011_0131-4)
MTHU008876 (LOINC Version 232-2)
65897001 (SNOMED CT 2011_0131-5)
C0581126 (UMLS CUI-1)
uncontrolled asthma despite therapy
Item
subjects will have Global Initiative for Asthma (GINA 2006) clinical features of uncontrolled asthma despite treatment with a minimum dose of 800 g beclomethasone dipropionate or equivalent inhaled corticosteroid per day plus one or more additional controller i.e. long-acting b-agonist, leukotriene antagonist or theophylline. Oral corticosteroids (not parenteral) as additional treatment at any dose are acceptable. The dose of inhaled and oral corticosteroids must have been stable within 4 weeks preceding Visit 1 (screening visit) and will be expected to remain stable for the duration of the study. If subjects are on single inhaler combination products at Visit 1 (e.g. fluticasone/salmeterol - Advair/Seretide or Symbicort (budesonide/formoterol) SMART) they must receive the two components as two separate inhaler medications for the purpose of the trial. This will facilitate withholding the long-acting b-agonist component before lung function and challenge testing (see Section 9.5.7). The GINA 2006 [14] levels of asthma control and treatment are described in Appendix 3.
boolean
C3862402 (UMLS CUI-1)
C0004906 (UMLS CUI-2)
C3248292 (UMLS CUI-3)
C0001644 (UMLS CUI-4)
C0039771 (UMLS CUI-5)
C0595726 (UMLS CUI-6)
C0205360 (UMLS CUI-7)
C0205195 (UMLS CUI-8)
FEV1 acceptable for AHR challenge test
Item
A forced expiratory volume in 1 second (FEV1) acceptable for AHR challenge tests (>= 60% of predicted normal) on the challenge days.
boolean
C0849974 (UMLS CUI-1)
C2733011 (UMLS CUI-2)
A provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) <= 4 mg/mL.
Item
A provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) <= 4 mg/mL.
boolean
C1714622 (UMLS CUI 2015AA)
Aged 18-80 years and are ambulatory and able to travel to the clinic.7. A 12-lead electrocardiogram (ECG) with no-clinically significant abnormalities.
Item
Aged 18-80 years and are ambulatory and able to travel to the clinic.7. A 12-lead electrocardiogram (ECG) with no-clinically significant abnormalities.
boolean
C0001779 (UMLS CUI 2015AA)
C0439841 (UMLS CUI 2015AA-2)
C0522054 (UMLS CUI 2011AA)
Clinical chemistry, haematology and urinalysis results within the laboratory reference ranges or deemed not clinically significant by the Investigator.
Item
Clinical chemistry, haematology and urinalysis results within the laboratory reference ranges or deemed not clinically significant by the Investigator.
boolean
C0438214 (UMLS CUI 2015AA)
Body weight of <= 130 kg.
Item
Body weight (observable entity)
boolean
C0005910 (UMLS CUI 2011AA)
27113001 (SNOMED CT 2011_0131)
MTHU001885 (LOINC Version 232)
No other clinically significant abnormality on history and clinical examination (see also Exclusion Criteria).
Item
No other clinically significant abnormality on history and clinical examination (see also Exclusion Criteria).
boolean
C2063084 (UMLS CUI 2015AA)
Able to comply with the requirements of the protocol.
Item
Able to comply with the requirements of the protocol.
boolean
C0085732 (UMLS CUI 2011AA)
371150009 (SNOMED CT 2011_0131)
C1321605 (UMLS CUI 2011AA-2)
405078008 (SNOMED CT 2011_0131-2)
C1709747 (UMLS CUI 2011AA-3)
Item Group
Exclusion Criteria
C0680251 (UMLS CUI 2011AA)
Experienced a severe exacerbation within 28 days preceding Visit 1.
Item
Experienced a severe exacerbation within 28 days preceding Visit 1.
boolean
C0038218 (UMLS CUI 2015AA)
C3828653 (UMLS CUI 2015AA-2)
Onset of uncontrolled seasonal allergy symptoms within 28 days preceding Visit 1. Subjects with a history of allergic rhinitis, seasonal allergy or oesophagitis must be optimally controlled and remain on a stable treatment regimen during the study.
Item
Onset of uncontrolled seasonal allergy symptoms within 28 days preceding Visit 1. Subjects with a history of allergic rhinitis, seasonal allergy or oesophagitis must be optimally controlled and remain on a stable treatment regimen during the study.
boolean
C0018621 (UMLS CUI 2015AA)
C1821205 (UMLS CUI 2015AA-2)
C3828653 (UMLS CUI 2015AA-3)
Participation in another study within five half lives or three months of the start of this study, whichever is the longer. This does not apply to methodological or observational studies in which no investigational medicinal product (IMP) was given.
Item
Participation in another study within five half lives or three months of the start of this study, whichever is the longer. This does not apply to methodological or observational studies in which no investigational medicinal product (IMP) was given.
boolean
C2348568 (UMLS CUI 2015AA)
Lower respiratory tract infection within six weeks of Visit 1.5.
Item
Lower respiratory tract infection within six weeks of Visit 1.5.
boolean
C0149725 (UMLS CUI 2011AA)
50417007 (SNOMED CT 2011_0131)
10024968 (MedDRA 14.1)
C0439230 (UMLS CUI 2011AA-2)
258705008 (SNOMED CT 2011_0131-2)
WK (HL7 V3 2006_05)
C1512346 (UMLS CUI 2011AA-3)
ENC (HL7 V3 2006_05-2)
Current smokers or ex-smokers with more than 10 pack-years
Item
Current smokers or ex-smokers with > 10 pack-years (number of pack years = (number of cigarettes per day/20) x number of years smoked, e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years).
boolean
77176002 (SNOMED CT 2011_0131)
10048880 (MedDRA 14.1)
8517006 (SNOMED CT 2011_0131-2)
10015572 (MedDRA 14.1-2)
315609007 (SNOMED CT 2011_0131-3)
260299005 (SNOMED CT 2011_0131-4)
MTHU024869 (LOINC Version 232)
258703001 (SNOMED CT 2011_0131-5)
D (HL7 V3 2006_05)
258707000 (SNOMED CT 2011_0131-6)
Y (HL7 V3 2006_05-2)
C0337664 (UMLS CUI-1)
C0337671 (UMLS CUI-2)
C1277691 (UMLS CUI-3)
Blood donation (> 550 mL) in the previous two months.
Item
Blood donation (> 550 mL) in the previous two months.
boolean
C0005794 (UMLS CUI 2011AA)
25179006 (SNOMED CT 2011_0131)
C0205156 (UMLS CUI 2011AA-2)
9130008 (SNOMED CT 2011_0131-2)
C0205448 (UMLS CUI 2011AA-3)
19338005 (SNOMED CT 2011_0131-3)
C0439231 (UMLS CUI 2011AA-4)
258706009 (SNOMED CT 2011_0131-4)
MO (HL7 V3 2006_05)
substance use
Item
Excessive intake of alcohol (as judged by the Investigator) or evidence of drug or solvent abuse.
boolean
160592001 (SNOMED CT 2011_0131)
61254005 (SNOMED CT 2011_0131-2)
18669006 (SNOMED CT 2011_0131-3)
26416006 (SNOMED CT 2011_0131-4)
10013654 (MedDRA 14.1)
LP36310-8 (LOINC Version 232)
305.90 (ICD-9-CM Version 2011)
61010005 (SNOMED CT 2011_0131-5)
417928002 (SNOMED CT 2011_0131-6)
10000341 (MedDRA 14.1-2)
C1705534 (UMLS CUI-1)
C0001948 (UMLS CUI-2)
other significant lung disease
Item
Subjects with a physician-diagnosis of any other significant lung disease, including a primary diagnosis of chronic obstructive pulmonary disease or bronchiectasis, or lung cancer, sarcoidosis, tuberculosis, pulmonary fibrosis and cystic fibrosis.
boolean
C0024115 (UMLS CUI-1)
C0750502 (UMLS CUI-2)
prohibited medications
Item
Concurrent medication from Visit 1 (screening visit) and for the duration of the study with any of the prohibited medications.
boolean
68405009 (SNOMED CT 2011_0131)
ENC (HL7 V3 2006_05)
MTHU024501 (LOINC Version 232)
C0013227 (UMLS CUI-1)
C3242263 (UMLS CUI-2)
Significant, uncontrolled disease including serious psychological disorders, chronic renal failure, uncontrolled hypertension
Item
Significant, uncontrolled disease including serious psychological disorders, chronic renal failure, uncontrolled hypertension
boolean
C0184774 (UMLS CUI 2015AA)
hypertension heart disease psoriasis or stroke
Item
hypertension heart disease, psoriasis or stroke
boolean
C0020538 (UMLS CUI-1)
C0033860 (UMLS CUI-2)
C0038454 (UMLS CUI-3)
Any factor which, in the opinion of the Investigator, would jeopardise the evaluation or safety or be associated with poor adherence to the protocol (i.e. inability to complete study diary, perform PEF measurements).
Item
Any factor which, in the opinion of the Investigator, would jeopardise the evaluation or safety or be associated with poor adherence to the protocol (i.e. inability to complete study diary, perform PEF measurements).
boolean
C3844688 (UMLS CUI 2015AA)
GP does not recommend participation
Item
The subject's primary care physician recommends the subject should not take part in the study.
boolean
446050000, 59058001 (SNOMED CT 2011_0131)
MTHU036724 (LOINC Version 232)
RMD (HL7 V3 2006_05)
116154003 (SNOMED CT 2011_0131-2)
PART (HL7 V3 2006_05-2)
110465008 (SNOMED CT 2011_0131-3)
C0017319 (UMLS CUI-1)
C3242266 (UMLS CUI-2)
Known hypersensitivity to CAT-354 or its components, to the challenge agents used in the study or to related drugs.
Item
Known hypersensitivity to CAT-354 or its components, to the challenge agents used in the study or to related drugs.
boolean
C0020517 (UMLS CUI 2015AA)
C0013227 (UMLS CUI 2015AA-2)

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial